Anju Bhardwaj MD FACC (@docbhardwaj) 's Twitter Profile
Anju Bhardwaj MD FACC

@docbhardwaj

Director HF ICU-ACTAT @memorialhermann; APD Gen Cards @UTHealthHouston SoMeEditor #JACCHF #JACCAdvances; Section-Editor #ASAIOJ. Tweets-my own, RT🚫Endorsement

ID: 97376117

linkhttps://scholar.google.com/citations?user=A20ysIkAAAAJ&hl=en calendar_today17-12-2009 05:49:27

11,11K Tweet

4,4K Takipçi

1,1K Takip Edilen

American College of Cardiology (@accintouch) 's Twitter Profile Photo

Nothing to ‘SCOFF’ at! New research out of #ESCCongress suggests fasting prior to cath lab procedures requiring conscious sedation may not be needed. Read more: bit.ly/3XgwbOy

Nothing to ‘SCOFF’ at! New research out of #ESCCongress suggests fasting prior to cath lab procedures requiring conscious sedation may not be needed. Read more: bit.ly/3XgwbOy
Rachna Kataria, MD (@rachkataria) 's Twitter Profile Photo

Love this contribution from the The Cardiogenic Shock Working Group, spearheaded by the person who introduced me to #CSWG - Khue Ton !! Congratulations to you and to all the CSWG PIs. Serial shock assessment is SO important and it’s great to have good quality data to support that. Navin Kapur

Love this contribution from the <a href="/CSWorkingGroup/">The Cardiogenic Shock Working Group</a>, spearheaded by the person who introduced me to #CSWG - <a href="/tonkhueMdPhd/">Khue Ton</a> !! Congratulations to you and to all the CSWG PIs. Serial shock assessment is SO important and it’s great to have good quality data to support that. <a href="/NavinKapur4/">Navin Kapur</a>
Stavros George Drakos (@stavrosdrakos) 's Twitter Profile Photo

#ESCCongress 2024, London, UK Can we identify who are the advanced HF patients that can recover their hearts ? Can we use a practical personalized tool to guide our recommendations for our patients’ therapeutic options: LVAD as bridge to recovery Vs. direct heart Tx or other ?

#ESCCongress 2024, London, UK

Can we identify who are the advanced HF patients that can recover their hearts ? 

Can we use a practical personalized tool to guide our recommendations for our patients’ therapeutic options: LVAD as bridge to recovery Vs. direct heart Tx or other ?
Stavros George Drakos (@stavrosdrakos) 's Twitter Profile Photo

On behalf of our multicenter team we presented at #ESCCongress 2024: Multicenter Model to Determine the Individualized Probability of Myocardial Recovery: The RecoverHeart Calculator THANK YOU to the 7 participating sites and co-investigators (see picture)

On behalf of our multicenter team we presented at #ESCCongress 2024:
Multicenter Model to Determine the Individualized Probability of Myocardial Recovery: The RecoverHeart Calculator

THANK YOU to the 7 participating sites and co-investigators (see picture)
Novi Tham (@slumberbell) 's Twitter Profile Photo

Happening now in Belgrade: dive into the latest breakthroughs in #hypertension drug therapies! 💊 Led by the expert chairs BiykemBozkurt and #AnthonyRodgers—! #ESCCongress

Happening now in Belgrade: dive into the latest breakthroughs in #hypertension drug therapies! 💊

Led by the expert chairs <a href="/BiykemB/">BiykemBozkurt</a> and #AnthonyRodgers—!

#ESCCongress
Richardkcheng (@richardkcheng2) 's Twitter Profile Photo

We describe our institutional experience for 4 allosensitized individuals for HALT-D. All 4 have done clinically well, with only 1 recipient developing low level DSA’s to date. The ISHLT Michelle Kittleson MD PhD Nasrien E. Ibrahim MD, MPH Khadijah Breathett, MD, MS, FACC, FAHA, FHFSA UWashington Heart Institute pubmed.ncbi.nlm.nih.gov/39222736/

We describe our institutional experience for 4 allosensitized individuals for HALT-D. All 4 have done clinically well, with only 1 recipient developing low level DSA’s to date. <a href="/ISHLT/">The ISHLT</a> <a href="/MKIttlesonMD/">Michelle Kittleson MD PhD</a> <a href="/DrNasrien/">Nasrien E. Ibrahim MD, MPH</a> <a href="/KBreathettMD/">Khadijah Breathett, MD, MS, FACC, FAHA, FHFSA</a> <a href="/UWMedHeart/">UWashington Heart Institute</a> pubmed.ncbi.nlm.nih.gov/39222736/
Sara Inglis (@sarainglismbbch) 's Twitter Profile Photo

New JACC Journals #JACCHF 🫀❤️‍🩹 ‼️Rapid uptitration of #GDMT ▪️⬇️ #HF-related morbidity & mortality  🌟Regardless of underlying HF risk profile DOI: 10.1016/j.jchf.2024.04.017

New <a href="/JACCJournals/">JACC Journals</a> #JACCHF 🫀❤️‍🩹

‼️Rapid uptitration of #GDMT
▪️⬇️ #HF-related morbidity &amp; mortality 
🌟Regardless of underlying HF risk profile

DOI: 10.1016/j.jchf.2024.04.017
Jenny Thibodeau, MD, MSCS (@jtthibs) 's Twitter Profile Photo

New in #JACCHF: REVIVED-BCIS2 showed PCI in addition to #GDMT in #ICM did not improve health status beyond 6 months compared with #GDMT alone. PCI should not be recommended for all ICM. jacc.org/doi/10.1016/j.… Editorial: jacc.org/doi/10.1016/j.…

New in #JACCHF: REVIVED-BCIS2 showed PCI in addition to #GDMT in #ICM did not improve health status beyond 6 months compared with #GDMT alone.  PCI should not be recommended for all ICM. 

jacc.org/doi/10.1016/j.…
Editorial: jacc.org/doi/10.1016/j.…
Munir S Janmohamed MD FACC, FHFSA (@munirjanmohamed) 's Twitter Profile Photo

New in #JACCHF: 🔥 Obesity & Weight Loss Strategies for Patients with Heart Failure Nice review of this important target in the management of #HF JACC Journals JACC HF: jacc.org/doi/10.1016/j.…

New in #JACCHF: 🔥

Obesity &amp; Weight Loss Strategies for Patients with Heart Failure 

Nice review of this important target in the management of #HF <a href="/JACCJournals/">JACC Journals</a> 

JACC HF: jacc.org/doi/10.1016/j.…
Texas Chapter - ACC (@txchapteracc) 's Twitter Profile Photo

TCACC Member Spotlight: Meet your WIC Section co-chairs Bindu Chebrolu and Anjlee Mehta. 🫀🩺Get involved with the Women in Cardiology section by clicking here: bit.ly/3Tc1s3J #HeartDoc #TexasMD #TXMD

TCACC Member Spotlight: Meet your WIC Section co-chairs <a href="/dr_chebrolu/">Bindu Chebrolu</a> and <a href="/anjleem/">Anjlee Mehta</a>. 🫀🩺Get involved with the Women in Cardiology section by clicking here:  bit.ly/3Tc1s3J  #HeartDoc #TexasMD #TXMD
Adrian da Silva (@adrianjdasilva) 's Twitter Profile Photo

In the #DOAC #LVAD (phase II trial): #Apixaban + ASA 81 mg (vs Warfarin + ASA 81 mg) was NOT associated with excess mortality or major hemocompatibility events in patients with HeartMate 3 For more details: shorturl.at/hD7AG

In the #DOAC #LVAD (phase II trial): #Apixaban + ASA 81 mg (vs Warfarin + ASA 81 mg) was NOT associated with excess mortality or major hemocompatibility events in patients with HeartMate 3

For more details: shorturl.at/hD7AG